537 related articles for article (PubMed ID: 35017177)
1. Therapeutics in the Pipeline Targeting
Grosso Jasutkar H; Oh SE; Mouradian MM
Pharmacol Rev; 2022 Jan; 74(1):207-237. PubMed ID: 35017177
[TBL] [Abstract][Full Text] [Related]
2. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
Kalsoom I; Wang Y; Li B; Wen H
Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
[TBL] [Abstract][Full Text] [Related]
3. Are Therapies That Target α-Synuclein Effective at Halting Parkinson's Disease Progression? A Systematic Review.
Rodger AT; ALNasser M; Carter WG
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446200
[TBL] [Abstract][Full Text] [Related]
4. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
5. The interaction between alpha-synuclein and mitochondrial dysfunction in Parkinson's disease.
Li HY; Liu DS; Zhang YB; Rong H; Zhang XJ
Biophys Chem; 2023 Dec; 303():107122. PubMed ID: 37839353
[TBL] [Abstract][Full Text] [Related]
6. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
Sengupta U; Kayed R
Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
[TBL] [Abstract][Full Text] [Related]
7. The misfolding mystery: α-synuclein and the pathogenesis of Parkinson's disease.
Negi S; Khurana N; Duggal N
Neurochem Int; 2024 Jul; 177():105760. PubMed ID: 38723900
[TBL] [Abstract][Full Text] [Related]
8. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
[TBL] [Abstract][Full Text] [Related]
9. An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.
Javed H; Kamal MA; Ojha S
CNS Neurol Disord Drug Targets; 2016; 15(10):1240-1252. PubMed ID: 27658511
[TBL] [Abstract][Full Text] [Related]
10. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
11. Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?
Kanaan NM; Manfredsson FP
J Parkinsons Dis; 2012; 2(4):249-67. PubMed ID: 23938255
[TBL] [Abstract][Full Text] [Related]
12. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
Benskey MJ; Perez RG; Manfredsson FP
J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
[TBL] [Abstract][Full Text] [Related]
13. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies.
Horvath I; Iashchishyn IA; Moskalenko RA; Wang C; Wärmländer SKTS; Wallin C; Gräslund A; Kovacs GG; Morozova-Roche LA
J Neuroinflammation; 2018 Jun; 15(1):172. PubMed ID: 29866153
[TBL] [Abstract][Full Text] [Related]
14. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
15. Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts.
Teil M; Arotcarena ML; Faggiani E; Laferriere F; Bezard E; Dehay B
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32138193
[TBL] [Abstract][Full Text] [Related]
16. The role of α-synuclein in neurodegenerative diseases: from molecular pathways in disease to therapeutic approaches.
Al-Mansoori KM; Hasan MY; Al-Hayani A; El-Agnaf OM
Curr Alzheimer Res; 2013 Jul; 10(6):559-68. PubMed ID: 23899170
[TBL] [Abstract][Full Text] [Related]
17. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
18. Targeting α-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics.
Savitt D; Jankovic J
Drugs; 2019 Jun; 79(8):797-810. PubMed ID: 30982161
[TBL] [Abstract][Full Text] [Related]
19. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease.
O'Hara DM; Kalia SK; Kalia LV
Crit Rev Clin Lab Sci; 2020 Aug; 57(5):291-307. PubMed ID: 32116096
[TBL] [Abstract][Full Text] [Related]
20. Alpha-Synuclein in Alcohol Use Disorder, Connections with Parkinson's Disease and Potential Therapeutic Role of 5' Untranslated Region-Directed Small Molecules.
Cahill CM; Aleyadeh R; Gao J; Wang C; Rogers JT
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33096655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
